Skip to main content

General Information about Hereditary Cancer and Public Health in Michigan

Inherited mutations, or changes, in a person's genetic information can cause some types of cancer. When a person carries one of these genetic changes, that person is at an increased risk for developing certain forms of the disease. Since these gene changes are often passed down from one generation to the next within a family, relatives of that individual may also have a higher risk for cancer.

An individual's family and personal health history can provide signs of hereditary cancer. These signs include:

  • A family member diagnosed with cancer before 50 years of age
  • 3 or more relatives with cancer on one side of the family
  • 3 or more generations affected with cancer
  • Any family member diagnosed with 2 or more primary cancers (for example, breast and ovarian cancer)
  • A male with breast cancer

 

HBOC/BRCA and Lynch Syndrome

Michigan's Cancer Genomics Program currently focuses on the two most common syndromes that cause hereditary cancer: Hereditary Breast and Ovarian Cancer (HBOC), which is due to changes in the BRCA genes; and Lynch Syndrome (LS), which is associated with higher risks of endometrial, ovarian, colorectal, and other types of cancer.

Many individuals and their family members who are at increased risk for these cancers may benefit from genetic counseling and earlier or more intense tumor screening and intervention.

Based on published literature and Michigan data, the following groups of adults are at greatest risk for hereditary cancers and are in most need of additional access to cancer genetic services in Michigan:

  1. First-degree relatives (parents, siblings, children) of individuals with a known BRCA or LS mutation
  2. Patients with a personal history of more than one primary cancer (i.e. breast and ovarian cancer; colorectal and endometrial)
  3. Patients with a personal history of ovarian cancer
  4. Patients with a personal history of breast cancer diagnosed at a young age
  5. Patients with a personal history of colorectal cancer

Michigan's Public Health Approach to Cancer Genomics

Cancer genomics was first identified as a priority in Michigan’s 2000-2002 statewide needs assessment and ensuing state genetics plan.

As a result of collaboration among the Michigan Department of Health and Human Services (MDHHS) Cancer Prevention and Control Section (CPCS), Michigan Cancer Surveillance Program (MCSP), Michigan Cancer Consortium (MCC) and clinical cancer genetic providers, the Michigan Cancer Genetics Alliance (MCGA) was established in 2002. The MCGA is a statewide association with over 140 members who strive to promote the appropriate application of genomics to improve cancer detection, prevention and treatments in Michigan.

In 2008, MDHHS was awarded a cooperative agreement with the Centers for Disease Control and Prevention (CDC) to create a comprehensive program to promote the adoption of appropriate cancer genomics practices by health care providers in the state. Since then, the program has received additional funding from the CDC for activities related to young breast cancer survivors (YBCS) and their relatives; BRCA surveillance, education, and health plan policy; colorectal cancer and Lynch Syndrome.

MDHHS Cancer Genomics Cooperative Agreements with CDC:

MDHHS also partners with other funded projects to promote cancer genomics best practices, including:

 

State Resources

 

National Resources

 

Support Groups

For patient support and information, you may want to visit:

 

Contact Us

Order cancer genomics resources.

If you have questions, call the MDHHS Genetic Information Line at 1-866-852-1247 or email genetics@michigan.gov. For cancer genetic counseling and testing services in your area, visit the Directory of Clinical Cancer Genetic Services in Michigan.

Genomics and Genetic Disorders Section 
Lifecourse Epidemiology and Genomics Division
P.O. Box 30195
333 S. Grand Avenue
Lansing, Michigan  48909-30195

 

Cancer Genomics Home Page

 

Funding for this program was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed in written materials, publications, or webpages do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Last updated: 6/23/2022